

The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells.

Maria Mamani-Matsuda, Antonio Cosma, Sandra Weller, Ahmad Faili,
Caroline Staib, Loïc Garçon, Olivier Hermine, Odile Beyne-Rauzy, Claire
Fieschi, Jacques-Olivier Pers, et al.

► **To cite this version:**

Maria Mamani-Matsuda, Antonio Cosma, Sandra Weller, Ahmad Faili, Caroline Staib, et al.. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells.: Long-lived B cell memory in the spleen.. Blood, American Society of Hematology, 2008, 111 (9), pp.4653-9. 10.1182/blood-2007-11-123844 . inserm-00311504

HAL Id: inserm-00311504

<https://www.hal.inserm.fr/inserm-00311504>

Submitted on 18 Aug 2008

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

THE HUMAN SPLEEN IS A MAJOR RESERVOIR FOR LONG-LIVED VACCINIA VIRUS-SPECIFIC MEMORY B CELLS.

Maria Mamani-Matsuda¹, Antonio Cosma^{2,3}, Sandra Weller¹, Ahmad Faili¹, Caroline Staib^{3,4}, Loïc Garçon⁵, Olivier Hermine⁶, Odile Beyne-Rauzy⁷, Claire Fieschi⁸, Jacques-Olivier Pers⁹, Nina Arakelyan¹⁰, Bruno Varet⁶, Alain Sauvanet¹¹, Anne Berger¹⁰, François Paye¹², Jean-Marie Andrieu¹⁰, Marc Michel¹³, Bertrand Godeau¹³, Pierre Buffet¹⁴, Claude-Agnès Reynaud^{1†} and Jean-Claude Weill^{1†}.

¹INSERM U783, "Développement du Système Immunitaire", Faculté de Médecine, Université Paris Descartes, Site Necker-Enfants Malades, 156 rue de Vaugirard, 75015 Paris, France

²Clinical cooperation group "Immune monitoring", Helmholtz Zentrum München-German Research Center for Environmental Health, Schneckenburgerstrasse 8, 81675 Munich, Germany

³Institute of Molecular Virology and Clinical cooperation group "Antigen-specific immunotherapy", Schneckenburgerstrasse 8, 81675 Munich, Germany

⁴Institute of Virology, Technical University, Schneckenburgerstrasse 8, 81675 Munich, Germany

⁵CHU Bicêtre, Service d'Hématologie, 78 rue du Général Leclerc, 94275 Le Kremlin-Bicêtre, France

⁶Hôpital Necker-Enfants Malades, Service d'Hématologie adulte, 149 rue de Sèvres, 75015 Paris, France

⁷CHU de Toulouse, Service de Médecine Interne et Immunopathologie, Place du Docteur Baylac, 31059 Toulouse cedex9, France

⁸Hôpital Saint-Louis, Unité d'Immunopathologie, 1 Av Claude Vellefaux, 75010 Paris, France

⁹CHU de Brest, Laboratoire d'Immunologie et Pathologie, 5 Av Foch, 29285 Brest cedex, France

¹⁰Hôpital Européen Georges Pompidou, Service de Cancérologie, 30 rue Leblanc, 75908 Paris cedex15, France

¹¹Hôpital Beaujon, Service de Chirurgie Digestive, 100 Blvd du Général Leclerc, 92110 Clichy, France

¹²Hôpital Saint Antoine, Service de Chirurgie Digestive, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France

¹³CHU Henri Mondor, Service de Médecine Interne, 51 Av du Maréchal de Lattre de Tassigny, 94000 Créteil, France

¹⁴Centre Médical, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris cedex 15, France

[†]To whom correspondence should be addressed. E-mail: reynaud@necker.fr /weill@necker.fr

Running Title: Long-lived B cell memory in the spleen.

Abbreviations: ITP, idiopathic thrombocytopenic purpura; MVA, modified vaccinia Ankara virus; RIT, rituximab treatment.

This research was originally published in *Blood*.

Mamani-Matsuda et al. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. *Blood*. 2008;111(9):4653-9.
© by the American Society of Hematology.

Abstract

The fact that you can vaccinate a child at 5 years of age and find lymphoid B cells and antibodies specific for this vaccination 70 years later remains an immunological enigma. It has never been determined how these long-lived memory B cells are maintained and whether they are protected by storage in a special niche. We report that, whereas blood and spleen compartments present similar frequencies of IgG⁺ cells, anti-smallpox memory B cells are specifically enriched in the spleen where they account for 0.24% of all IgG⁺ cells, *i.e.* 10-20 million cells, more than 30 years after vaccination. They represent in contrast only 0.07% of circulating IgG⁺ B cells in blood, *i.e.* 50-100,000 cells. An analysis of patients either splenectomized or rituximab-treated confirmed that the spleen is a major reservoir for long-lived memory B cells. No significant correlation was observed between the abundance of these cells in blood and serum titers of anti-vaccinia virus antibodies in this study, including in the contrasted cases of B-cell depleting treatments. Altogether, these data provide evidence that in humans, the two arms of B cell memory -long-lived memory B cells and plasma cells- have specific anatomical distributions -spleen and bone marrow- and homeostatic regulation.

Introduction

Long-lived memory B cells and specific antibodies have been reported to persist in the body for decades after specific vaccination.¹⁻³ One of the central questions concerning this phenomenon concerns the maintenance of this memory in the absence of repeated stimulations with the original vaccine. Experiments in mice suggested that the survival of memory B cells depended neither on constant cell proliferation nor on the presence of the immunizing antigen.^{4,5} It was therefore assumed that these cells remain quiescent for long periods of time, but nonetheless react very rapidly if they encounter the immunizing antigen. It has also been suggested that the presence of specific serum antibodies is directly linked to the presence of the corresponding memory B cells. In this model, each new antigenic stimulation provides bystander T cell help for the previously generated memory B cells, leading to the differentiation of some of these cells into Ig-secreting plasmocytes.⁶ An alternative explanation for the continued presence of serum antibodies a long time after the initial pathogen encounter has also been put forward, according to which each vaccination induces both the immediate differentiation of plasmocytes and the formation of long-lived plasma cells.^{7,8} These memory plasma cells would survive in bone marrow and would be replaced, at a certain rate, by plasmablasts generated in response to new pathogens.⁹

Smallpox vaccination is considered an ideal model for studies of the basis of long-term cellular and humoral memory.¹⁰ Vaccinia virus was successfully used to eradicate variola virus, the etiologic agent of smallpox. As smallpox vaccination was stopped in the mid 1970s and smallpox was eradicated worldwide in 1977,¹¹ we can assume that people have not been re-exposed to the pathogen since then. Using ELISPOT assays following *in vitro* cell stimulation, we studied the maintenance of the vaccinia virus-specific memory B cell pool in the blood and spleen of normal individuals, and in those of patients who had

undergone B cell-targeted immune interventions. We show here that long-lived memory B cells have their own central reservoir, the spleen, and seem to display their own homeostatic regulation, independent of the presence of the corresponding plasmocytes.

Materials and Methods

Viruses

The modified vaccinia virus Ankara (MVA), which was used as the antigen in the B-cell ELISPOT assay, was amplified in chicken embryo fibroblasts and purified by centrifugation on a sucrose cushion. Alternatively, highly purified MVA preparations for use in ELISA were produced by centrifugation on two successive sucrose gradient cushions. Titers were determined by plaque assays on confluent chicken embryo fibroblast monolayers grown in six-well tissue culture plates.¹²

Patients and controls

Approval for this research was granted by the “Comité de protection des personnes Ile-de-France II”. Written informed consent was obtained from all patients. The characteristics of the subjects, including age, sex, diagnosis and medication taken at the time of sample collection are detailed in Supplemental Tables S1-S3. Nine splenectomized patients (V10 to V18: 4 benign and 3 malignant pancreatic tumors, 2 idiopathic thrombocytopenic purpura, ITP) displayed normal numbers of B cells and had not undergone any chemotherapy. Nine rituximab-treated patients (RTX1 to RTX9) suffered chronic ITP, Sjogren’s syndrome or non-Hodgkin’s lymphoma. Rituximab regimen is detailed in Supplemental Table S2 (3 patients received light corticotherapy). Chemotherapy treatment, when given (RTX3, RTX4), was stopped at least 25 months before sample collection, except for V19. Bone

marrow samples were obtained from diagnosis aspirations. For all patients, B cell content and proportions of IgG⁺ B cells are detailed in Supplemental Tables S1-S3. As a control, we obtained blood samples from 16 healthy subjects from the blood bank (*Etablissement Français du Sang*): 9 vaccinated individuals (35 to 59 years old) and 7 non-vaccinated individuals (all under the age of 28 years). Control spleens were retrieved after splenectomy of non-vaccinated patients (microspherocytosis and physical trauma, 7 and 17 year-old respectively).

Isolation of cells and serum

Spleen samples were recovered in complete medium (RPMI-1640, 100 mU/ml penicillin, 100 µg/ml streptomycin (all from Invitrogen) and 10% fetal calf serum (FCS, HyClone, Logan, UT) after surgery and were stored at 4°C until processing. In some cases, the entire spleen was maintained under physiological perfusion for 6 h before cell isolation, as described by Buffet *et al.*,¹³ with no influence in results. Cell suspensions were obtained by mechanical dissociation in complete medium. Peripheral blood and bone marrow aspirates were collected in heparin or EDTA tubes for cell isolation. In all experiments, mononuclear cells (MNC) from blood, bone marrow aspirates or spleen cell suspensions were isolated by centrifugation on a Ficoll-Hypaque density gradient. Red blood cells were lysed and the remaining cells were washed with 2% FCS in PBS and resuspended in complete medium containing 50 µM β-mercaptoethanol. Cell viability after isolation was determined by counting with Trypan Blue exclusion and only samples with viability exceeding 90% were considered. In the case of patient RTX6 (B cell content below 1%), the splenic preparation was enriched for B cells, using the B cell-negative isolation kit (Dyna-Biotech, Oslo,

Norway) according to the manufacturer's recommendations. Such enrichment was performed in order to obtain a measurable value in ELISPOT assay. Serum was prepared by clotting blood collected in SST tubes (BD Diagnosis, Franklin Lakes, NJ) or by treating one volume of plasma with one volume of BC thrombin reagent (Dade Behring, Marburg, Germany) for 10 min at room temperature. Serum was then inactivated by heating for 30 min at 56°C and frozen in aliquots.

Flow cytometry

Cells were routinely labelled with the following antibodies: fluorescein isothiocyanate (FITC)-conjugated rabbit F(ab')₂ anti-human IgG (F0056) or the corresponding isotype control (X0929) from Dako (Glostrup, Denmark), phycoerythrin (PE)-conjugated anti-human CD27 antibody (clone 1A4-CD27) and PE-cyanin 5.1 (PC5)-anti human CD19 antibody (clone J4.119) from Beckman-Coulter (Fullerton, CA), allophycocyanin (APC) anti-CD19 (clone HIB19) from BD Pharmingen (San Diego, CA). When indicated, labelled cells were incubated with 7-AAD (BD Pharmingen) 10 minutes before analysis in order to exclude dead cells. Cells were analyzed on a FACScan or FACSCalibur, with CellQuest Pro software (BD Biosciences, San Diego, CA).

Memory B cell assay

This procedure was adapted from that described by Crotty *et al.*¹⁴ Briefly, PBMC or MNC were plated at 5×10^5 cells /ml in 24-well (5×10^5 cells) or 6-well (5×10^6 cells) plates, in complete culture medium supplemented with 10 ng/ml pokeweed mitogen extract (PWM, batch 1303H, ICN, MP Biomedicals, Aurora, OH), a 1/10,000 dilution of fixed *Staphylococcus aureus*, Cowan extract (SAC, Sigma-Aldrich, St-Louis, MO) and 6 µg/ml

fully phosphothioated CpG (ODN-2006,¹⁵ Proligo-Sigma-Aldrich). Cells were cultured for six days at 37°C, under an atmosphere containing 5% CO₂. They were then washed and used to seed 96-well plates: from each culture well of 5 x 10⁵ cells, 1/5 of the cells were used for IgG ELISPOT and 4/5 were used for MVA or KLH ELISPOT. From culture wells of 5 x 10⁶ cells, 1/20 was used for IgG ELISPOT and 19/20 was used for MVA or KLH ELISPOT. Samples were serially diluted in culture medium, in triplicate, before transfer to ELISPOT plates. Multiscreen 96-well filter plates (MSIPS4510, Millipore, Bedford, MA) were coated by incubation overnight at 4°C with 100 µl of 3 x 10⁸ MVA pfu /ml, 2.5 µg/ml keyhole limpet hemocyanin (KLH, Pierce Biochemicals) or 10 µg/ml anti-human Ig polyvalent antibody (Caltag Laboratories, Burlingame, CA). ELISPOT was performed with 1 µg/ml biotinylated goat anti-human IgG Fc (H10015, Caltag Laboratories) followed by 5 µg/ml HRP-conjugated Avidin D (Vector Laboratories, Burlingame, CA) and developed using 3-amino-9-ethylcarbazole (Sigma-Aldrich). Spots were counted in wells showing more than 3 specific spots, in an ELISPOT reader, with AID software (version 3.5, Autoimmun Diagnostika GmbH, Germany). When detected, IgG secreting cell numbers from the corresponding unstimulated wells (cells cultivated in complete medium alone) were subtracted to the values obtained in stimulated cells. Each experiment was conducted in 3 independent wells and the results are the mean of the 3 ELISPOT values obtained. Data are presented as the percentage of total IgG⁺ memory B cells specific for vaccinia virus. When no vaccinia virus-specific spot was detectable, a value of <*x* was assigned, with *x* corresponding to the frequency obtained if one vaccinia-specific spot was detected at the lowest dilution.

ELISA

Maxisorp plates (Nunc, Roskilde, Denmark) were coated by incubation overnight at 4°C with 10^6 MVA pfu/well. Plates were blocked by incubation with 10% FCS in PBS for 1 h at 37°C. Triplicates of serum samples were serially diluted in PBS-0.05% Tween20 (PBST) and incubated for 1 h at 37°C. Plates were washed four times in PBST, and were then incubated for 1 h at 37°C with peroxidase-conjugated goat anti-human IgG Fc (Nordic Immunology, Tilburg, The Netherlands) at a concentration of 2 µg/ml in PBST. Plates were washed four times in PBST and incubated with OPD (Sigmafast OPD tablets, Sigma-Aldrich) for 10 min at room temperature. The reaction was stopped by adding 1.8 N H₂SO₄, and optical density was measured at a wavelength of 490 nm. The determination of serum titer is detailed in Supplemental Figure S1.

Statistical Methods

Non parametric Kruskal-Wallis two-sided score test was used to compare the frequency of vaccinia virus-specific memory B cells between blood and spleen and between controls and splenectomized patients, as well as serum titers of vaccinia virus antibody between the different groups studied. For the 23 vaccinated individuals for whom both parameters were known, we estimated the Spearman coefficient of correlation R^2 between anti-vaccinia virus antibody titers and the frequency of vaccinia virus-specific memory B cells. All analyses were performed using SAS Software 9.1 (SAS Institute, Cary, NC).

Results

Anti-vaccinia virus memory B cells are concentrated in the spleen

We first compared the proportion of memory B cells against vaccinia virus in the blood and spleen several decades after vaccination, in samples obtained from vaccinated (Table 1, V1-V20) or non-vaccinated (Table 1, C1-C9) individuals. The modified vaccinia virus Ankara (MVA) is a replication-deficient strain of vaccinia virus that was tested as a safer vaccine for smallpox vaccination.¹⁶ It was used throughout this study for the ELISPOT and ELISA assays, to assess cellular and serological anti-smallpox/vaccinia virus memory. Blood or splenic mononuclear cells were analyzed by ELISPOT against MVA, after 6 days of *in vitro* polyclonal stimulation, as described by Crotty *et al.*¹⁴ We determined the proportion of anti-vaccinia virus-specific B cells as the ratio of anti-MVA IgG⁺ cells to total IgG⁺ cells (Figure 1A). The members of the vaccinated cohort were aged between 31 and 75 years, whereas the non-vaccinated controls were all under the age of 28 years (Table 1). We first confirmed previous results,¹ showing that a median of 0.07% of circulating IgG⁺ memory B cells were specific for vaccinia virus in the blood of individuals vaccinated more than 30 years previously, with the values observed lying between 0.01 and 0.16% (Figure 1B; Table 1). The absence of anti-vaccinia virus memory B cells in the non-vaccinated controls indicated an absence of cross-reactive responses induced by closely related viruses. We retrieved splenic fragments, mostly from patients who had undergone surgery for a pancreatic tumor (see description of patients in Supplemental Table S1). Splenic mononuclear cells from nine patients vaccinated at least 30 years ago, and from two non-vaccinated controls (7 and 17 years old) were analyzed with the anti-MVA ELISPOT assay. The proportion of anti-vaccinia virus memory B cells in the spleen was much higher, at 0.24%, with values ranging from 0.07 to 0.62% (Figure 1B; V10-V18 in Table 1). No

vaccinia virus-specific IgG secreting cells were detected in control culture with unstimulated cells either from blood or from spleen. In three patients from whom both splenic and blood samples could be obtained, the proportion of memory B cells in the spleen and blood differed by a factor of three to ten (Figure 1B insert; V10, V13, V18, in Table 1), these differences being observed even in cases in which the frequency of splenic memory B cell was in the lower range (Table 1, V13 and V18).

Variable impact of rituximab-induced B cell depletion on anti-vaccinia virus memory

B cell survival

It has been reported that the circulation is depleted of most of its B cells following treatment with rituximab, a B cell-depleting anti-CD20 antibody. However, the extent of this depletion seems to be more variable in lymphoid organs.¹⁷⁻¹⁹ B cell recovery in the blood starts about six months after the end of the treatment, with normal levels reached after 12 to 20 months. We analyzed the blood of five patients treated with rituximab 25 to 39 months previously (Table 2; Figure 1C). No circulating anti-vaccinia virus memory B cells were detected in two patients (RTX3: <0.007%, RTX5: <0.04%), whereas such cells were detected in two others (RTX4, RTX1), albeit at a low frequency (0.01 and 0.04%). Surprisingly, in the last patient (RTX2), memory B cells specific for vaccinia virus were found 26 months after rituximab treatment (RIT; 2 cycles, see description of patients in Supplemental Tables S2) at a frequency much higher (0.32%) than that observed in the blood of normal individuals analyzed several decades after vaccination. An increase in serum B-cell-activating factor (BAFF) concentration has been reported after RIT in some patients.²⁰ Serum BAFF level was normal in patient RTX2 (not shown), leaving us with no

clear explanation for these findings. Thus, most patients treated with rituximab displayed a lower frequency of anti-vaccinia virus memory B cells in their blood.

Some splenic anti-vaccinia virus memory B cells can resist rituximab treatment

Given the highly variable pattern of memory B cell recovery after RIT, and assuming that the spleen could act as a major reservoir for these cells, we decided to determine the frequency of residual memory B cells in the spleen after RIT. We focused on three cases of idiopathic thrombocytopenic purpura (ITP) who underwent splenectomy after a failure to respond to treatment. One patient (RTX6, Table 2) was splenectomized three months after RIT. No B cells were detected in his blood and the percentage of B cells in the spleen was very low (around 0.1%). These cells were found to be almost exclusively IgG⁺ CD27⁺ (Figure 2), thus suggesting a memory phenotype. After *in vitro* stimulation, anti-vaccinia virus memory B cells were detected, amounting to 0.14% of total IgG⁺ B cells (Table 2). The second patient (RTX7, Table 2) underwent splenectomy six months after the end of RIT. B cells were beginning to reappear in his blood (1.6%, versus 10% in controls) and spleen (10% versus 40% in controls). Memory B cells against vaccinia virus were not detectable in his blood and amounted to 0.06% in his spleen. In the third patient (RTX8, Table 2) in which the spleen was retrieved 15 months after the end of RIT, B cells recovered to normal values in blood and spleen (Supplemental Table S2) but vaccinia virus-specific memory B cells could only be found in the spleen at a frequency of 0.06% of total IgG secreting cells. These three cases evoke that a small pool of splenic anti-vaccinia virus memory B cells (a few tens of thousands memory B cells) have resisted to RIT along with other IgG⁺ switched B cells. As the spleen replenishes with newly formed IgG⁺ B cells, this pool may tend to dilute itself.

Splenectomy affects the circulating long-lived memory B cell pool

If long-lived memory B cells are principally maintained in the spleen, then the frequency of these cells should be significantly lower in patients that have been splenectomized several years ago. We collected blood samples from five patients, who had undergone splenectomy 7 to 50 years previously (see description of patients in supplemental Table S3). The levels of circulating anti-vaccinia virus memory B cells were all below the median of the control values (Figure 1C; Table 2, SPL4: no detectable anti-vaccinia virus memory B cells, SPL1: 0.01%, SPL3: 0.009%, SPL2, for which small accessory spleens were detected: 0.04% and SPL5: 0.06%). These results suggest that splenectomy may lead to a consistent loss of long-lived memory B cells and that this deficiency can persist even several decades after the surgical procedure. Nevertheless, these cells can still be found, albeit at diminished levels, in the blood of most of these patients, suggesting the existence of other minor storage sites outside the spleen.

Further evidence to support this hypothesis is provided by the case of a rituximab-treated patient who underwent splenectomy two months after four cycles of RIT and who was analyzed 36 months after splenectomy. A small proportion of circulating anti-vaccinia virus memory B cells could be detected in this patient (RTX9: 0.02%, Table 2).

In two cases in which it was possible to analyze a bone marrow sample not contaminated with malignant cells or blood, we detected no significant enrichment of anti-vaccinia virus memory B cells over average values for blood (V19: 0.04%, V20: 0.02%, Table 1).

No significant correlation between vaccinia virus-specific serum antibody titers and blood memory B cells

We estimated the correlation between the proportion of memory B cells and the level of specific antibodies against vaccinia virus, by using ELISA to determine serum anti-vaccinia virus antibody titers in the blood of most of the subjects analyzed in this study (Tables 1 and 2). A large proportion of the patients vaccinated more than 30 years ago had measurable levels of anti-vaccinia virus antibodies, consistent with the findings of previous reports.¹⁻³ We took a value of 0.075, the median value for non-vaccinated individuals, as the threshold below which levels of IgG against vaccinia virus were considered negative (Table 1 and Supplemental Figure S1). Three patients with no anti-vaccinia virus antibodies were found to have vaccinia virus-specific memory B cells in their blood (V6, Table 1 and RTX4, SPL5, Table 2). Conversely, in three patients with a reasonably high level of anti-vaccinia virus antibodies, no circulating anti-vaccinia virus memory B cells could be detected in their blood (V13, Table 1 and SPL4, RTX3, Table 2). No significant correlation was found in this study between the proportion of memory B cells and the titer of antibodies specific for vaccinia virus (Figure 3, for n=23 individuals, $R^2=-0.03$, p -value=0.88).

Discussion

We studied the persistence of vaccinia virus-specific memory B cells in the blood and spleen of normal individuals and of patients who had undergone B cell-targeted immune interventions, splenectomy or anti-CD20 mediated B cell depletion.

In individuals vaccinated with the vaccinia virus during their childhood (*i.e.*, more than 30 years before this study) about 0.24% of splenic IgG⁺ B cells recognize this pathogen. This

proportion is significantly higher than that for the blood (about 0.07%, consistent with previous reports^{1,3}). Taking into account the size of the blood and splenic B cell compartments (approximately 5×10^8 and 4×10^{10} B cells respectively, with 10 to 20% IgG⁺ B cells), there are, on average, around 0.5 to 1×10^5 memory B cells against vaccinia virus circulating in the blood of vaccinated individuals, and 1 to 2×10^7 such cells in the spleen. Assuming that all pathogens display similar numbers of immunodominant B cell epitopes, thereby engaging similar numbers of memory B cells, this suggests that the splenic B cell compartment has an overall memory against 10^2 to 10^3 different pathogens. The values proposed for the repertoire of long-lived plasma cells in humans are of the same order of magnitude.²¹ It has been suggested that some long-lived plasma cells may be regularly replaced by newly formed plasmablasts, although it remains unclear how this replacement takes place.⁹ A similar turnover may occur for memory B cells, but again, we know little of the basic mechanism of memory formation and the signals conferring on these cells a shorter or longer existence within the individual.

We could not study lymph nodes or Peyer's patches from vaccinated individuals, raising questions about the possibility of other secondary lymphoid organs constituting an additional reservoir for long-lived memory B cells. There was a severe reduction, although not a complete loss, of circulating anti-vaccinia virus memory B cells in most splenectomized patients. This suggests that these cells survive as such in the blood or that there are other accessory niches outside the spleen. Rituximab, a chimeric human/mouse anti-CD20 antibody, has become a major treatment for B cell-related lymphomas and autoimmune disorders. Two to four years after RIT, most patients presented much lower levels of circulating anti-vaccinia virus memory B cells. Analysis of the spleen a few months after RIT showed the presence of residual B cells, with the IgG⁺ phenotype only,

including a small proportion of long-lived memory B cells, despite the total absence of circulating B cells. Strikingly, a low level of circulating anti-vaccinia virus memory B cells was also observed in one patient, three years after a splenectomy performed 2 months after the completion of rituximab treatment. Since B cell depletion was still complete in the blood at the time of splenectomy, this unique case strengthens the view that there are other storage sites for memory B cells, but that these sites do not seem to compensate quantitatively for the absence of the spleen. Bone marrow has been identified as a preferential niche for long-lived plasma cells and for some memory T and B cells.^{7,8,22,23} We did not detect any specific enrichment of vaccinia virus memory B cells in the two bone marrow samples that we have analyzed. Overall, these results suggest that the spleen is a major niche for long-lived memory B cells but that despite drastic B cell depleting treatment such as RIT or splenectomy, these cells can slowly reappear in the blood. These treatments therefore do not seem to result in the systematic eradication of the B cell memory carried by these patients, notably the one related to childhood vaccinations. Consistent with this interpretation, the response to recall antigens seemed to be strongly decreased by rituximab treatment in one study of lymphoma patients,²⁴ whereas this response was found to be preserved in another study.²⁵

The concept of two layers of long-term humoral memory sustained by the existence of long-lived memory B cells and long-lived plasma cells emerged some years ago^{7,8} and has subsequently been strongly supported by experimental data.²⁶ It has also been proposed that the maintenance of antibodies several decades after a vaccination or an infection was due to a constant production by non specific stimulation of memory B cells.⁶ In the later case, there should be a quantitative correlation between the frequency of memory B cells and the level of serum antibodies. In several reports in which these parameters were analyzed after

vaccination or natural infections, the strength of the correlation varied considerably,^{1,3,27-29} suggesting that bystander stimulation of memory B cells into short lived plasma cells was unlikely to be a general mechanism. In the present study, in which it was possible to analyze more strongly contrasting situations, no correlation was observed for the 23 patients for whom both serum titers of anti-vaccinia virus antibodies and memory B cells could be determined. In fact, a complete dissociation was observed in several cases, with anti-vaccinia virus antibodies detected in the total absence of the corresponding memory B cells, or memory B cells being present in the absence of the corresponding antibodies. This observation gives additional support to the proposal that long-lived memory B cells and long-lived plasma cells in humans are independent entities, with long-lived plasma cells able to survive for several decades independently of the presence of memory B cells of the same specificity.^{3,8,30} Nevertheless, B cell memory does not seem to be a uniform phenomenon and one can not exclude that some antigen-specific or non specific stimulation of long-lived memory B cell could also contribute to the production of antibodies.^{6,31}

Many unanswered questions remain concerning the homeostatic regulation of long-lived memory B cells. If the spleen is indeed, as proposed here, a main reservoir for these cells, then most memory B cells may only react to a specific recall pathogen once it reaches the spleen, whereas the circulating memory B cells and neutralizing antibodies will provide a first line of defense at the beginning of infection.

Acknowledgments

We thank Drs. B. Ranque and A. Alcaïs for statistical analysis, S. Arguès for assistance with ELISA, Dr. Puydupin from the *EFS St-Vincent de Paul* for providing blood samples and Dr. Alyanakian from *Hôpital Necker-Enfants Malades* for serological determinations. We thank Q. Gueranger for helpful suggestions, and L. Abel and J.L. Casanova for critical reading of the manuscript. This work was supported by the *Fondation Princesse Grace*, the *Agence Nationale pour la Recherche* (“B cell memory”, MIIM program) and the *Ligue Contre le Cancer (Equipe labellisée)*. M.M.-M. was supported by successive fellowships from the *Fondation de France*, the *Fondation Singer-Polignac* and the *Région Ile-de-France*. C.A.R. is a Research Director at the *Centre National de la Recherche Scientifique*. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author contributions

M.M.-M. conducted all the experiments, analyzed the data and contributed to the writing of the manuscript; A.C., S.W. and A.F. contributed to research and critical discussions; C.S. produced MVA; L.G., O.H., O.B-R., C.F., J-O.P., N.A., B.V., A.S., A.B., F.P., J.-M.A., M.M., B.G. and P.B. participated to the selection and collection of patient samples; M.M. and B.G. provided clinical support for the study; C.-A.R. and J.-C.W. share senior scientific responsibility and authorship.

Conflict-of-interest disclosure: Authors declare that they have no conflict of interest.

Correspondence: Claude-Agnès Reynaud / Jean-Claude Weill, INSERM U783, Université Paris Descartes, Faculté de Médecine, site Necker-Enfants Malades, 156 rue de Vaugirard, 75015 Paris, France ; e-mail : reynaud@necker.fr / weill@necker.fr

References

1. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. *J Immunol.* 2003;171:4969-4973.
2. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. *Nat Med.* 2003;9:1131-1137.
3. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. *N Engl J Med.* 2007;357:1903-1915.
4. Maruyama M, Lam KP, Rajewsky K. Memory B-cell persistence is independent of persisting immunizing antigen. *Nature.* 2000;407:636-642.
5. Schitteck B, Rajewsky K. Maintenance of B-cell memory by long-lived cells generated from proliferating precursors. *Nature.* 1990;346:749-751.
6. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. *Science.* 2002;298:2199-2202.
7. Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. *Nature.* 1997;388:133-134.
8. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. *Immunity.* 1998;8:363-372.
9. Odendahl M, Mei H, Hoyer BF, et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. *Blood.* 2005;105:1614-1621.
10. Slifka MK. Immunological memory to viral infection. *Curr Opin Immunol.* 2004;16:443-450.
11. Smith GL, McFadden G. Smallpox: anything to declare? *Nat Rev Immunol.* 2002;2:521-527.
12. Staib C, Drexler I, Ohlmann M, Wintersperger S, Erfle V, Sutter G. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. *Biotechniques.* 2000;28:1137-1142, 1144-1136, 1148.
13. Buffet PA, Milon G, Brousse V, et al. Ex vivo perfusion of human spleens maintains clearing and processing functions. *Blood.* 2006;107:3745-3752.
14. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. *J Immunol Methods.* 2004;286:111-122.
15. Hartmann G, Weeratna RD, Ballas ZK, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. *J Immunol.* 2000;164:1617-1624.
16. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. *J Gen Virol.* 1991;72 (Pt 5):1031-1038.
17. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. *Clin Immunol.* 2007;122:62-74.
18. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP. The effect of desensitization protocols on human splenic B-cell populations in vivo. *Am J Transplant.* 2007;7:402-407.

19. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. *Immunobiology*. 2002;206:519-527.
20. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. *Ann Rheum Dis*. 2007;66:700-703.
21. Hofer T, Muehlinghaus G, Moser K, et al. Adaptation of humoral memory. *Immunol Rev*. 2006;211:295-302.
22. Paramithiotis E, Cooper MD. Memory B lymphocytes migrate to bone marrow in humans. *Proc Natl Acad Sci U S A*. 1997;94:208-212.
23. Di Rosa F, Pabst R. The bone marrow: a nest for migratory memory T cells. *Trends Immunol*. 2005;26:360-366.
24. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. *Blood*. 2002;100:2257-2259.
25. Bearden CM, Agarwal A, Book BK, et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. *Am J Transplant*. 2005;5:50-57.
26. Radbruch A, Muehlinghaus G, Luger EO, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. *Nat Rev Immunol*. 2006;6:741-750.
27. Leyendeckers H, Odendahl M, Lohndorf A, et al. Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. *Eur J Immunol*. 1999;29:1406-1417.
28. Nanan R, Heinrich D, Frosch M, Kreth HW. Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory B-lymphocytes. *Vaccine*. 2001;20:498-504.
29. Quinn CP, Dull PM, Semenova V, et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. *J Infect Dis*. 2004;190:1228-1236.
30. Manz RA, Lohning M, Cassese G, Thiel A, Radbruch A. Survival of long-lived plasma cells is independent of antigen. *Int Immunol*. 1998;10:1703-1711.
31. Zinkernagel RM. On natural and artificial vaccinations. *Annu Rev Immunol*. 2003;21:515-546.

Table 1. Serum anti-vaccinia virus antibodies and anti-vaccinia virus memory B cells in blood, spleen and bone marrow

Individual	Age (years)	Anti-vaccinia virus IgG (serum dilution ratio)†	% vaccinia virus-specific memory B cells		
			In blood	In spleen	In bone marrow
Non-vaccinated					
C1	28	0.22	<0.001*		
C2	27	0.07	<0.001*		
C3	24	nd	<0.013*		
C4	24	0.04	<0.030*		
C5	23	0.12	<0.010*		
C6	20	0.08	<0.004*		
C7	20	0.05	<0.010*		
C8	17	nd	<0.018*	<0.002*	
C9	7	nd	nd	<0.005*	
Median		0.075			
Vaccinated					
V1	59	0.27	0.037		
V2	56	0.28	0.110		
V3	53	1	0.088		
V4	53	0.38	0.112		
V5	53	0.10	0.134		
V6	48	0.07	0.062		
V7	48	0.49	0.010		
V8	45	nd	0.117		
V9	35	0.73	0.155		
V10	75	1.16	0.047	0.456	
V11	74	0.53	nd	0.157	
V12	66	ni	nd	0.309	
V13	59	0.40	<0.012*	0.068	
V14	58	0.29	nd	0.301	
V15	57	nd	nd	0.616	
V16	53	nd	nd	0.230	
V17	45	0.21	nd	0.238	
V18	31	ni	0.031	0.088	
V19	53	0.68	0.022		0.038
V20	47	0.10	0.067		0.018
Median		0.380	0.067	0.238	

*Maximum estimate for individuals for whom memory B cells were undetectable (see the Methods section), †Dilution factor with respect to the positive control, see definition in the Materials and Methods section, nd: not done, ni: not interpretable (patient receiving intravenous Ig at the time of sample collection).

Table 2. Serum anti-vaccinia virus antibodies and anti-vaccinia virus memory B cells in rituximab-treated (RTX) and splenectomized (SPL) patients

Patient	Age at sample collection	Time after rituximab (months)	Anti-vaccinia virus IgG (serum dilution ratio)	% vaccinia virus-specific memory B cells	
				In blood	In spleen
RTX1	83	39	0.12	0.044	
RTX2	61	26	0.84	0.317	
RTX3	55	29	0.32	<0.007*	
RTX4	45	25	0.05	0.010	
RTX5	42	32	0.25	<0.041*	
RTX6	79	3	ni	-†	0.140
RTX7	70	6	ni	-†	0.063
RTX8	62	15	0.47	-†	0.064
RTX9	67	2 + 36 [‡]	0.40	0.015	
Patient	Age at sample collection	Years after splenectomy	Anti-vaccinia virus IgG (serum dilution ratio)	% vaccinia virus-specific memory B cells in blood	
SPL1	60	50	1.10	0.010	
SPL2	59	44	0.20	0.041	
SPL3	52	7	0.34	0.009	
SPL4	46	35	0.28	<0.009*	
SPL5	35	30	0.01	0.062	

*Maximum estimate for individuals for whom memory B cells were undetectable. †B cell depletion precluded blood analyses. ‡Patient was splenectomized 2 months after rituximab treatment. Blood was collected 36 months after splenectomy. Other definitions as in Table 1, see clinical description in Supplemental Tables S2-S3.

Figure Legends

Figure 1. Vaccinia virus-specific memory B cells are enriched in the spleen and decreased in blood after splenectomy or rituximab treatment.

ELISPOT assays were performed after 6 days of *in vitro* polyclonal stimulation of mononucleated cells. (A) ELISPOT showing a 10-fold enrichment of anti-vaccinia memory B cells in the spleen. MVA, anti-IgG or an unrelated antigen (KLH) were used as coating antigens. Blood and spleen samples from patient V10 (Table 1). Shown is one representative ELISPOT well out of three, corresponding to the indicated dilution for each antigen. (B) Frequency of anti-vaccinia virus memory B cells in blood and spleen, determined by ELISPOT assay. The insert shows data from three patients (V10, V13, V18, Table 1) for whom both blood and spleen were analyzed. (C) Frequency of anti-vaccinia virus memory B cells determined by ELISPOT assay in blood of splenectomized (SPL) and rituximab-treated (RTX) patients, compared to healthy donors (Control, same samples as in panel B). Bold lines indicate the median values for groups with sample size >5. Dashed symbols correspond to maximum estimates for individuals for whom specific memory B cells were undetectable (see Materials and Methods). *p* are determined by a non parametric Kruskal-Wallis two-sided test.

Figure 2. Rituximab-resistant splenic B cells are CD27⁺IgG⁺.

The B cell content was analyzed at the time of splenectomy, three months after four cycles of rituximab (patient RTX6, Table 2). (A) CD19 and CD27 staining of blood PBMC. (B) Staining of the splenic MNC. From left to right: 7-AAD staining; CD19 and CD27 staining gated on 7-AAD-negative cells; IgG and isotype control staining of CD19-positive

7-AAD-negative cells. 80% of the splenic CD19⁺ B cells were of the IgG⁺CD27⁺ memory phenotype.

Figure 3. No correlation between anti-vaccinia virus antibodies and memory B cells in blood.

Anti-vaccinia virus IgG titer and anti-vaccinia virus memory B cell frequency from the same blood samples were compared. Data are from n=23 individuals including 12 control individuals (circles), 5 splenectomized patients (diamonds) and 6 rituximab-treated patients (triangles) for whom both values were measurable. Dashed symbols correspond to maximum estimates for individuals for whom memory B cells were undetectable (see Materials and Methods) and anti-vaccinia virus serum titer were positive. Shown is the Spearman coefficient of correlation R^2 for the n=23 samples (p -value=0.88).

Figure 1




Figure 2




Figure 3

